Literature DB >> 23203247

FDA approves 11C-choline for PET in prostate cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23203247

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  15 in total

1.  Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

Authors:  Chung Yao Yu; Bhushan Desai; Lingyun Ji; Susan Groshen; Hossein Jadvar
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

Review 2.  Choline metabolism-based molecular diagnosis of cancer: an update.

Authors:  Kristine Glunde; Marie-France Penet; Lu Jiang; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Expert Rev Mol Diagn       Date:  2015-04-28       Impact factor: 5.225

Review 3.  Molecular imaging of urogenital diseases.

Authors:  Steve Y Cho; Zsolt Szabo
Journal:  Semin Nucl Med       Date:  2014-03       Impact factor: 4.446

4.  [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Elena Incerti; Paola Mapelli; Margarita Kirienko; Alberto Briganti; Giorgio Gandaglia; Francesco Montorsi; Luigi Gianolli; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-20       Impact factor: 9.236

5.  Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.

Authors:  M Colombié; L Campion; C Bailly; D Rusu; T Rousseau; C Mathieu; L Ferrer; N Rousseau; F Kraeber-Bodéré; C Rousseau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-21       Impact factor: 9.236

6.  Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.

Authors:  Julia Whitman; Isabel E Allen; Emily K Bergsland; Insoo Suh; Thomas A Hope
Journal:  J Nucl Med       Date:  2021-01-15       Impact factor: 10.057

7.  18F-Fluorocholine Positron Emission Tomography/Computed Tomography is a Highly Sensitive but Poorly Specific Tool for Identifying Malignancy in Thyroid Nodules with Indeterminate Cytology: The Chocolate Study.

Authors:  Renaud Ciappuccini; Idlir Licaj; Audrey Lasne-Cardon; Emmanuel Babin; Dominique de Raucourt; David Blanchard; Vianney Bastit; Virginie Saguet-Rysanek; Justine Lequesne; Damien Peyronnet; Jean-Michel Grellard; Bénédicte Clarisse; Stéphane Bardet
Journal:  Thyroid       Date:  2020-12-23       Impact factor: 6.568

Review 8.  Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.

Authors:  Richard L Wahl; Panithaya Chareonthaitawee; Bonnie Clarke; Alexander Drzezga; Liza Lindenberg; Arman Rahmim; James Thackeray; Gary A Ulaner; Wolfgang Weber; Katherine Zukotynski; John Sunderland
Journal:  J Nucl Med       Date:  2021-01       Impact factor: 11.082

9.  How we read FCH-PET/CT for prostate cancer.

Authors:  Jean-Mathieu Beauregard; Alexis Beaulieu
Journal:  Cancer Imaging       Date:  2016-12-06       Impact factor: 3.909

10.  11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series.

Authors:  Laure Michaud; Karim A Touijer; Audrey Mauguen; Michael J Zelefsky; Michael J Morris; Serge K Lyashschenko; Jeremy C Durack; John L Humm; Wolfgang A Weber; Heiko Schöder
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 11.082
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.